Literature DB >> 34338713

Reassessing the Role of Routine Urine Drug Screening in Opioid Use Disorder Treatment.

Michael A Incze1,2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34338713     DOI: 10.1001/jamainternmed.2021.4109

Source DB:  PubMed          Journal:  JAMA Intern Med        ISSN: 2168-6106            Impact factor:   21.873


× No keyword cloud information.
  3 in total

1.  Negative Impact of Amphetamine-Type Stimulant Use on Opioid Agonist Treatment Retention in Ontario, Canada.

Authors:  Kristen A Morin; Frank Vojtesek; Shreedhar Acharya; David C Marsh
Journal:  Front Psychiatry       Date:  2021-12-20       Impact factor: 4.157

2.  Utilizing telemedicine during COVID-19 pandemic for a low-threshold, street-based buprenorphine program.

Authors:  Robert Harris; Amanda Rosecrans; Meredith Zoltick; Catherine Willman; Ronald Saxton; Margaret Cotterell; Joy Bell; Ingrid Blackwell; Kathleen R Page
Journal:  Drug Alcohol Depend       Date:  2021-11-26       Impact factor: 4.492

3.  Evaluating the association between urine drug screening frequency and retention in opioid agonist treatment in Ontario, Canada: a retrospective cohort study.

Authors:  Kristen A Morin; John R Dabous; Frank Vojtesek; David Marsh
Journal:  BMJ Open       Date:  2022-10-12       Impact factor: 3.006

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.